Avadel Pharmaceuticals plc was registered as an Irish private limited company on December 1, 2015 and re-registered as an Irish public limited company on November 21, 2016. Avadel Pharmaceuticals plc is a specialty pharmaceutical company with a long history in drug delivery, focusing on developing safer and more effective formulations that address unmet pharmaceutical needs during research. The company focuses on: (1) the development and licensing of five functional and proprietary drug delivery platforms, (2) the development of novel, high-value products based on drug delivery platforms, and (3) the development, approval and marketing of niche brand and generic products in the United States after the acquisition of Eclat Pharmaceuticals.